<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    RehabPath Inc.

    RehabPath Inc.

    We exist to make the first step in a family’s path to recovery the right step thro...

    We exist to make the first step in a family’s p...

    Amount Raised:    $26,162.00
    Fundraising Status:    EC
    Filing Type:    CF
    Marker Therapeutics, Inc.

    Marker Therapeutics, Inc.

    We are a clinical-stage immuno-oncology company specializing in the development an...

    We are a clinical-stage immuno-oncology company...

    Filing Type:    PU
    Morphic Holding, Inc.

    Morphic Holding, Inc.

    Morphic Therapeutic is leading the development of a new generation of oral integri...

    Morphic Therapeutic is leading the development ...

    Filing Type:    PU
    Cytonics Corp

    Cytonics Corp

    Cytonics, founded in 2006, is a private research and development company focused o...

    Cytonics, founded in 2006, is a private researc...

    Amount Raised:    $3,300,000.00
    Fundraising Status:    EC
    Filing Type:    CF
    Quidel Corporation

    Quidel Corporation

    Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of di...

    Quidel Corporation (Nasdaq: QDEL) is a Californ...

    Filing Type:    PU
    IntriCon Corporation

    IntriCon Corporation

    For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...

    For more than 40 years, IntriCon has been meeti...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Compugen Ltd.

    Compugen Ltd.

    Compugen is a drug discovery company with a unique, broadly applicable, predictive...

    Compugen is a drug discovery company with a uni...

    Filing Type:    PU
    Neoleukin Therapeutics, Inc.

    Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...

    Neoleukin is a biopharmaceutical company creati...

    Filing Type:    PU
    Allogene Therapeutics, Inc.

    Allogene Therapeutics, Inc.

    Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...

    Allogene Therapeutics is a clinical stage biote...

    Filing Type:    PU
    Veru Inc.

    Veru Inc.

    Our strategy is to be known as “the prostate cancer company”. We aspire to be ...

    Our strategy is to be known as “the prostate ...

    Filing Type:    PU
    Champions Oncology, Inc.

    Champions Oncology, Inc.

    Champions Oncology, Inc. is engaged in the development of advanced technology solu...

    Champions Oncology, Inc. is engaged in the deve...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.